Compare ROL & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROL | DGX |
|---|---|---|
| Founded | 1948 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 23.2B |
| IPO Year | 1994 | 1996 |
| Metric | ROL | DGX |
|---|---|---|
| Price | $37.32 | $243.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $64.73 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 5.2M | 832.7K |
| Earning Date | 04-22-2026 | 04-21-2026 |
| Dividend Yield | 1.32% | ★ 1.82% |
| EPS Growth | 13.54 | ★ 13.78 |
| EPS | 0.52 | ★ 5.08 |
| Revenue | $2,161,220,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $10.42 | $7.53 |
| Revenue Next Year | $8.86 | $3.77 |
| P/E Ratio | $70.98 | ★ $48.11 |
| Revenue Growth | 7.23 | ★ 11.78 |
| 52 Week Low | $35.83 | $171.18 |
| 52 Week High | $66.14 | $245.68 |
| Indicator | ROL | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 72.61 |
| Support Level | $36.59 | $191.82 |
| Resistance Level | $61.59 | N/A |
| Average True Range (ATR) | 0.79 | 4.47 |
| MACD | 0.30 | -0.24 |
| Stochastic Oscillator | 74.32 | 82.80 |
Rollins is a global leader in route-based pest control services, with operations primarily in the United States and across North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US and Canada, with near-national coverage. It also has a portfolio of other brands, which it uses to reach customers through alternative sales channels. Residential pest and termite prevention accounts for the majority of Rollins' services, reflecting its ongoing focus on the US and Canadian markets.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.